BioSpace News Archive

Arbutus Biopharma Corporation today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 12, 2023.

Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARK CT.

iCAD, Inc today announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr. Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is Finding the Breast Cancers Radiologists Fear the Most,” the live event will take place on Thursday, July 20 at 10 am ET.

INmune Bio, Inc. has been invited to discuss drug development strategies in aging and rejuvenation at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany on July 17, 2023.

Apnimed, Inc. announced today that it will be participating in a fireside chat at the William Blair Conference, Transitioning Biotech Breakthroughs to Commercial Success, taking place virtually on Tuesday, July 18, 2023 at 8 a.m. ET.

LianBio today announced a clinical supply agreement with AstraZeneca in China to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill hospitalized patients.

Petauri Health, a New York–based, purpose-built pharmaceutical services platform, announced that it has named Mridul Malhotra to the dual role of Chief Strategic Officer and Global Head: Evidence, Value, and Access.

Apollo Medical Holdings, Inc. announced that it and its affiliated professional entity have entered into a definitive agreement to acquire assets relating to Texas Independent Providers, LLC.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced a favorable coverage policy from Highmark Inc.